Targeting the HGF/Met signalling pathway in cancer.
Cecchi
Fabiola
F
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. cecchif@mail.nih.gov
Rabe
Daniel C
DC
Bottaro
Donald P
DP
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017228:Hepatocyte Growth Factor / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors / Q000502:physiology*; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors / Q000502:physiology*
D000970:Antineoplastic Agents; C066855:HGF protein, human; D047428:Protein Kinase Inhibitors; D017978:Receptors, Growth Factor; D017228:Hepatocyte Growth Factor; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met